The Efficacy of Radial Extracorporeal Shockwave Therapy on Knee Osteoarthritis
NCT ID: NCT03344770
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE2
44 participants
INTERVENTIONAL
2017-10-20
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For this trial, patients with knee osteoarthritis, after signing the informed consent form and having their demographic and baseline information collected, will be randomly allocated into one of both treatment arms: radial extracorporeal shockwave therapy (rESWT) or sham radial extracorporeal shockwave therapy. Then, they will undertake three sessions of rESWT, for three weeks, i.e. one session per week.
Patients will be assessed prior to the therapy, one week after the end of the therapy and three months after the end of the therapy, and the primary outcome of this study is the functional change measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) validated in Portuguese, three months after the end of the therapy.
Secondary outcomes, will be the change of pain, the change of pressure pain tolerance threshold, change in diffuse noxious inhibitory control (DNIC), and thermographic changes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis
NCT02197962
Extracorporeal Focused Shock Wave Therapy for Primary Knee Osteoarthritis
NCT02904785
Radial Versus Focused Extracorporeal Shock Wave in the Treatment of Knee Osteoarthritis
NCT03921749
Effect of Extracorporeal Shock Wave in the Treatment of Knee Osteoarthritis
NCT03962270
The Effect of Cryotherapy in Pain Control, Function and Quality of Life in Individuals With Knee Osteoarthritis
NCT02725047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active rESWT
Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
Active rESWT
5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
Sham rESWT
Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
Sham rESWT
5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active rESWT
5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
Sham rESWT
5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Onset knee pain with moderate or severe intensity: Visual Analogue Scale (VAS) \> 4;
* Onset knee pain over 3 months prior to the inclusion;
Exclusion Criteria
* Presence of fibromyalgia;
* Presence of systemic inflammatory rheumatic diseases;
* History of neoplasia;
* Presence of clinical diseases in other joints;
* Ongoing use of anticoagulant drugs.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marta Imamura
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marta Imamura
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Imamura, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto de Medicina Física e Reabilitação HCFMUSP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto de Medicina Fisica e Reabilitacao HCFMUSP
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
72067817.8.0000.0068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.